PDF Archive

Easily share your PDF documents with your contacts, on the Web and Social Networks.

Share a file Manage my documents Convert Recover PDF Search Help Contact



Morepen CBI .pdf


Original filename: Morepen CBI.pdf
Title: Morepen Laboratories Scores No. 1 Position Globally for its Bulk Drug Montelukast | PharmaTutor

This PDF 1.4 document has been generated by http://www.convertapi.com, and has been sent on pdf-archive.com on 12/10/2016 at 14:39, from IP address 112.196.x.x. The current document download page has been viewed 310 times.
File size: 471 KB (7 pages).
Privacy: public file




Download original PDF file









Document preview


QUICKLINKS

Latest News

Alzheimer’s disease could be treated with gene therapy, suggests animal study

PreviousPauseNext

Home » Morepen Laboratories Scores No. 1 Position Globally for its Bulk Drug Montelukast

Morepen Laboratories Scores No. 1 Position Globally for its Bulk Drug
Montelukast
Posted on: 11 May 2016 By: Gayatri Mahajan

Ads by Google

Freshers Jobs
Jobs in Pharmacy

Morepen Laboratories Ltd. has established a leadership position for its anti-asthmatic bulk drug Montelukast in the global market. As per the latest report
published by a global research firm - QYR Research, Morepen is the No.1 supplier globally in terms of total quantity sold, followed by Mylan and TAPI (Teva) who
appear on the second and third position respectively.
Morepen’s global sales for Montelukast Sodium stood at 16240 kgs in the calender year 2015,
resulting in a market share of 23 per cent (approx.) compared to Mylan’s and Teva’s 12 per cent
each, the report claims.
This was disclosed by Mr. Sushil Suri, Chairman and Managing Director, Morepen Laboratories
Ltd. after the company’s board meeting, which discussed and took on record the fourth quarter
and annual results of the company for the financial year 2015-16. “After attaining leadership in
Loratadine, by being world’s largest generic supplier of the bulk drug, Morepen Laboratories Ltd.
has attained a leadership in its second molecule -Montelukast,” he pointed out.
Morepen Laboratories Ltd. has reported an over 25-fold increase in its net profit for the financial
year ended March 31, 2016. The net profit increased from Rs. 58 lakhs in FY 2014 -15 to Rs.
15.78 crore in FY 2015-16. The total operating revenue in FY 2015-16 stood at Rs. 452.46 crore
as against Rs. 370.26 crore in the previous fiscal, registering a growth of 22.20 per cent.
For the fourth quarter ended March 31, 2016, net profit rose to Rs. 2.77 crore on a total operating
revenue of Rs. 123.59 crore as compared to a loss of Rs. 3.72 crore on a total operating revenue
of Rs. 85.36 crore in the corresponding quarter of the previous fiscal.
Morepen’s EBIDTA increased by 36.30 per cent in fiscal 2015-16 at Rs. 65.38 crore and the cash
surplus (i.e. EBDTA) rose by 40 per cent at Rs. 54.96 crore compared to Rs. 47.95 crore and Rs.
39.31 crore respectively, in the previous fiscal.
“Enhanced focus on cost reduction and adoption of innovative processes resulted in this
remarkable turnaround, putting the company back on the profit trajectory,” Mr. Suri said.
Q4 marked excellent performance in all business segments particularly bulk drugs (API) which has grown by more than 50%, while Home Diagnostics and
Finished Dosages segments also outperformed and registered a remarkable growth of 35% and 40% respectively adding to the outstanding quarterly
performance.
converted by Web2PDFConvert.com

Ads by Google R & D Jobs
Pharmacy
Jobs at C
QA Jobs
Total revenues from the bulk drug Montelukast in Q4 grew by more than 90% at Rs. 25.71 crore. Thus, Montelukast registered the highest growth amongst bulk
drugs followed by Loratadine and Atorvastatin, which grew by 20% and 37% respectively, over Q4 last year. In the FY 2015-16, total revenue from Montelukast
crossed Rs. 74 crores and is likely to cross Rs. 100 crore mark in fiscal 2016-17.

Exports: With strategic international positioning, the company’s export turnover has crossed Rs. 200 crores in FY 2015-16, registering a growth of 32 per cent. The
exports turnover is expected to grow by 25% Year-on-Year and is likely to cross Rs. 250 crore in fiscal 2016-17.
In the home health category, Morepen’s Diagnostics division grew by 23% Year-on-year. The company cemented its leadership in Blood Glucose Monitors market
by registering 41% growth in fiscal 2015-16 with a top line of Rs.33.38 crores. It sold more than 30 million test strips in fiscal 2015-16. Looking at increasing
incidence of diabetic cases in India, this segment offers great opportunity for growth in the coming years.
<< Pharma News
Subscribe to PharmaTutor News Alerts by Email >>

Ads by Google

Jobs Vacancies
Pharmacy Tech Salary
Tags: Pharma News Industry News Business Wire India

Add new comment

converted by Web2PDFConvert.com

Career as Drug
Inspector (91 posts)
at Food & D...

Recruitment for
Pharmacists (81
posts) in State...

Applications are
invited for
Pharmacist...

Vacancies for
Pharmacists (168
posts) in RRB - ...

Requirement of
Pharmacist at
Directorate of Hea...

Immediate Walk in
interview in
Glenmark Pharma...

Job for
B.Pharm/M.Pharm/

Search PharmaTutor

RECOMMENDED JOBS
Pharmatutor Alerts
Recruitment for Fresher Pharmacists (25 posts) at AIMS
Wanted Area Business Manager- Vaccines in Abbott
Work as Technical Officer in National Institute of Biologicals
Opportunity for Sr Medical & Scientific Affairs Specialist in Roche
Pharmaceutical Development Manager Require at Grünenthal
Walk in interview for the post of Junior Research Fellow at NIRRH
Wanted Area Sales Manager - Mass Market at Johnson & Johnson

converted by Web2PDFConvert.com

Recruitment for Study Monitor/Clinical Research Associate in CDSA - Govt. Jobs | Emoluments Up to Rs. 46,000 pm
Career for Pharmacist Trainer in Raje Healthcare - 10 posts | Pharm.D Freshers only apply
Working opportunity as Technical Officer (Pharmacist) at world health oraganization
Subscribe to this Feed

Latest News
Pharmatutor News Alerts
Alzheimer’s disease could be treated with gene therapy, suggests animal study
Triple-drug chemotherapy with topotecan helps preserve vision in retinoblastoma patients
US FDA approved LBT's Automated Plate Assessment System (APAS®)
Novartis' Tafinlar + Mekinist show superior overall survival benefit in phase III COMBI-v study
Novartis ALK+ metastatic NSCLC therapy Zykadia® extends progression-free survival in Phase II study
Nicox get CRL from the FDA Related to GMP on NDA for AC-170
Are natural alternatives to estrogen replacement therapy safe
Nivolumab reduces symptoms in relapsed metastatic head and neck cancer
Zydus collaborate with Neovii to launch Grafalon in India
Innovus Pharma start clinical programme evaluating safety and efficacy of Vesele with sildenafil
Subscribe to this Feed

SUBSCRIBE WITH US
Enter your email address:

Subscribe
Do Not Forget to Verify
(Click on Subscription link in your inbox)

converted by Web2PDFConvert.com

BROWSE BY JOBS
Production Jobs
R&D Jobs
F&D Jobs
Sales & Marketing
QA Jobs
QC Jobs
Faculty Jobs
CRO Jobs
DRA Jobs
IPR Jobs
IT Jobs
Walk-in Jobs
Government Jobs
Hosptial Pharmacist

QUICK LINKS
Course wise Alerts
D.Pharm Alerts
B.Pharm Alerts
B.Sc Alerts
M.Pharm Alerts
M.Sc Alerts
MBA Alerts
Pharm.D Alerts
Ph.D Alerts
converted by Web2PDFConvert.com

City wise Alerts
Ahmedabad Alerts
Baddi Alerts
Bangalore Alerts
Chandigarh Alerts
Chennai Alerts
Delhi Alerts
Hyderabad Alerts
Jaipur Alerts
Kolkata Alerts
Mumbai Alerts
Pune Alerts

USER LOGIN
Username *

Password *

Register |

Forgot Password?
Log in

LATEST ISSUE - OCT 16

ACTIVE FORUM TOPICS
Urgent Requirements for Medical Coding in top MNC in Chennai...
Vacancies for Quality control and production in Hyderabad for freshers
clinical SAS programme
Career prospects of medical representative
Basic Tips to Refine Medical Writing Skills | Medical Writing Training
More

RESEARCH NEWS

converted by Web2PDFConvert.com

Triple-drug chemotherapy with topotecan helps preserve vision in retinoblastoma patients
Are natural alternatives to estrogen replacement therapy safe
Nivolumab reduces symptoms in relapsed metastatic head and neck cancer
Janssen present New Phase 3 Data In Treatment of Moderate to Severe Plaque Psoriasis
Sanofi Pasteur received approval for Dengvaxia® dengue vaccine
more

POPULAR ARTICLES
QUALITY CONTROL TESTING OF PACKAGING MATERIALS
MICROBIAL ASSAY OF ANTIBIOTICS
REGISTRATION DOSSIER OF PHARMACEUTICALS
INDUSTRIAL HAZARDS AND SAFETY MEASURES
NOVEL DRUG DELIVERY SYSTEM

JOBS BY SUBJECTS
Biology
Biochemistry
Biotechnology
Chemistry
Pharmaceutics
Pharmacognosy
Pharmacology
Microbiology

Privacy Policy | Disclaimer | Terms of Use | Advertise | Sitemap | Send Feedback
Copyright © 2008-2016, PharmaTutor Edu Labs

converted by Web2PDFConvert.com


Related documents


morepen cbi
morepen cbi sushil suri
dr morepen cbi
morepen sushil suri
morepen cbi
sushil suri cbi


Related keywords